Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
| Autor: | D Pode, Alberto Gabizon, Ayala Hubert, Olga Lyass |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Side effect Urology Antineoplastic Agents Pilot Projects Disease-Free Survival Prostate cancer Pharmacokinetics Internal medicine medicine Humans Pharmacology (medical) Doxorubicin Treatment Failure Infusions Intravenous Stomatitis Aged Skin Pharmacology Cardiotoxicity Drug Carriers business.industry Prostatic Neoplasms Middle Aged medicine.disease Hormones Hair loss Area Under Curve Toxicity Liposomes business medicine.drug |
| Zdroj: | Anti-cancer drugs. 11(2) |
| ISSN: | 0959-4973 |
| Popis: | Doxil, a doxorubicin formulation of polyethylene glycol-coated liposomes, has anti-tumor activity against Kaposi's sarcoma and other solid tumors with mild myelosuppression, minimal hair loss and a low risk of cardiotoxicity. Non-liposomal doxorubicin has modest activity in hormone-refractory prostate cancer (HRPC) with considerable toxicity. A pilot study of Doxil was conducted in 15 patients with HRPC. Doxil was administered i.v. using two regimes of equal dose intensity, either 45 mg/m2 every 3 weeks or 60 mg/m2 every 4 weeks. Plasma levels of doxorubicin were analyzed in 10 patients. The most common side effect was stomatitis with a higher incidence at the 60 mg/m2 dose level. In contrast, hand-foot syndrome was more frequent and severe in patients treated with the 3 week schedule of 45 mg/m2. Three patients responded to treatment (based on objective response in one patient and reduction of PSA level greater than 50% in the other two) and two patients had stable disease, all of them receiving 60 mg/m2. Pharmacokinetic analysis shows a proportional increase of plasma drug levels with dose and the characteristic long circulation time of Doxil with half-lives in the range of 3 days, somewhat longer than previously reported. In conclusion, Doxil at 60 mg/m2 every 4 weeks appears to be active against HRPC, but severe mucocutaneous toxicities prevented further investigation of this regime. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|